Forte Biosciences' Vitiligo Triumph: A High-Stakes Bet on Broad Autoimmune Potential

Related Articles

Blue Origin's $130 Billion Valuation: A High-Stakes Bet on Future Potential, Not Current Performance

3 months ago

Neuronetics: A High-Stakes Turnaround Play with 143% Upside Potential

2 months ago

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

5 months ago

Super Micro's Cash Hole: A High-Stakes Bet on AI Infrastructure

2 months ago

Category

You may also like

Stock News•2 months ago

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Argenx agreed to buy Forte Biosciences in an all-cash deal, gaining a promising autoimmune drug candidate to bolster its pipeline.

FBRX

Share

Stock News•3 months ago

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Forte Biosciences' FB102 showed statistically significant improvement in vitiligo at Week 24, after a 12-week treatment period, signaling potential efficacy.

FBRX

Share

Stock News•3 months ago

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune's EVO756 CSU miss casts doubt on its pipeline, but a healthy balance sheet and positive Phase 2a AD data for EVO301 provide a potential catalyst.

EVO

Share